Thymopentin
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 10, 2021 (NCT04771013)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lamina-associated polypeptide 2, isoforms beta/gammaImmunity, active
LAP2B immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04771013 | Phase 2 | Feb 10, 2021 | Pontificia Universidad Catolica de Chile, Universidad Católica de Honduras |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pontificia Universidad Catolica de Chile | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Universidad Católica de Honduras | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1